{"result": "(\"entity\"<|>CANCER PREVENTION-II<|>EVENT<|>Cancer Prevention-II is a study that associates obesity with increased mortality rates from various types of cancer.)\n##\n(\"entity\"<|>EE. UU.<|>GEO<|>EE. UU. refers to the United States, where 14% of cancer mortality in men and 20% in women is attributed to overweight.)\n##\n(\"entity\"<|>AVGERINOS KI<|>PERSON<|>Avgerinos KI is one of the authors of the referenced study on obesity and cancer risk.)\n##\n(\"entity\"<|>SPYROU N<|>PERSON<|>Spyrou N is one of the authors of the referenced study on obesity and cancer risk.)\n##\n(\"entity\"<|>MANTZOROS CS<|>PERSON<|>Mantzoros CS is one of the authors of the referenced study on obesity and cancer risk.)\n##\n(\"entity\"<|>DALAMAGA M<|>PERSON<|>Dalamaga M is one of the authors of the referenced study on obesity and cancer risk.)\n##\n(\"entity\"<|>N Engl J Med<|>ORGANIZATION<|>N Engl J Med is a medical journal that published studies related to obesity and cancer.)\n##\n(\"entity\"<|>NAT REV CANCER<|>ORGANIZATION<|>Nat Rev Cancer is a medical journal that published studies related to obesity and cancer.)\n##\n(\"entity\"<|>BUPROPION<|>ORGANIZATION<|>Bupropion is a medication used in the treatment of obesity and acts as a norepinephrine-dopamine reuptake inhibitor.)\n##\n(\"entity\"<|>NALTREXONA<|>ORGANIZATION<|>Naltrexone is a medication used in the treatment of obesity that acts as an opioid antagonist.)\n##\n(\"entity\"<|>ORLISTAT<|>ORGANIZATION<|>Orlistat is a medication that inhibits gastrointestinal lipases, blocking the digestion of dietary triglycerides.)\n##\n(\"entity\"<|>FENTERMINE<|>ORGANIZATION<|>Fentermina is a noradrenergic agonist used in combination with topiramate for weight loss.)\n##\n(\"entity\"<|>TOPIRAMATO<|>ORGANIZATION<|>Topiramate is an antiepileptic drug that is combined with fentermina for weight loss.)\n##\n(\"relationship\"<|>CANCER PREVENTION-II<|>EE. UU.<|>The study Cancer Prevention-II provides statistics on cancer mortality in the United States related to obesity<|>7)\n##\n(\"relationship\"<|>AVGERINOS KI<|>CANCER PREVENTION-II<|>Avgerinos KI is one of the authors of the Cancer Prevention-II study<|>8)\n##\n(\"relationship\"<|>SPYROU N<|>CANCER PREVENTION-II<|>Spyrou N is one of the authors of the Cancer Prevention-II study<|>8)\n##\n(\"relationship\"<|>MANTZOROS CS<|>CANCER PREVENTION-II<|>Mantzoros CS is one of the authors of the Cancer Prevention-II study<|>8)\n##\n(\"relationship\"<|>DALAMAGA M<|>CANCER PREVENTION-II<|>Dalamaga M is one of the authors of the Cancer Prevention-II study<|>8)\n##\n(\"relationship\"<|>BUPROPION<|>NALTREXONA<|>Bupropion is used in combination with naltrexone for the treatment of obesity<|>6)\n##\n(\"relationship\"<|>FENTERMINE<|>TOPIRAMATO<|>Fentermina is combined with topiramate for effective weight loss treatment<|>6)\n##\n(\"relationship\"<|>NALTREXONA<|>BUPROPION<|>Naltrexone acts as an antagonist to allow the effects of bupropion to persist<|>7)\n##\n(\"relationship\"<|>ORLISTAT<|>CANCER PREVENTION-II<|>Orlistat is mentioned in the context of treatments related to obesity and cancer risk<|>5)\n##\n(\"relationship\"<|>N Engl J Med<|>CANCER PREVENTION-II<|>N Engl J Med published studies related to obesity and cancer, including Cancer Prevention-II<|>6)\n##\n(\"relationship\"<|>NAT REV CANCER<|>CANCER PREVENTION-II<|>Nat Rev Cancer published studies related to obesity and cancer, including Cancer Prevention-II<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: mayores son para endometrio y carcinoma esofágico.\n\nEl sobrepeso y la obesidad son los principales determinantes del cáncer tras el consumo de tabaco. En EE. UU., un 14% de la mortalidad por cáncer en hombres y un 20% en mujeres son atribuibles al exceso ponderal. En el estudio Cancer Prevention-II, los hombres con obesidad mórbida se asociaron con un 52% de mortalidad respecto a normopeso (mayor en páncreas [RR 2,61] y hepatocarcinoma [RR 4,52]). En las mujeres con obesidad mórbida, el cáncer se asoció con un 62% de mayor mortalidad; en concreto destaca el carcinoma renal (RR 4,75) y el de endometrio (RR 6,5).\n\nTabla 2. Riesgo relativo de incremento de riesgo para diferentes tipos de cáncer, según niveles de evidencia\n\n| TIPO DE CÁNCER | EVIDENCIA ALTA | TIPO DE CÁNCER | EVIDENCIA MEDIA |\n|----------------|----------------|----------------|-----------------|\n| Endometrio | 3,5 | Estómago | 2,0 |\n| Esófago | 3,0 | Vesícula biliar | 2,0 |\n| Renal | 2,5 | Páncreas | 1,7 |\n| Colorrectal | 1,5-2,0 | Hígado | 1,5-4,0 |\n| Mama (posmenopausia) | 1,5 | Mieloma múltiple | 1,5-3,0 |\n| Ovario | 1,0-1,5 | Meningioma | 1,5-3,0 |\n| Tiroides | 1,0-1,5 | | |\n\nValores promedios basados en Calle EE & Kaaks (Nat Rev Cancer. 2004) y Lauby-Secretan B, et al. (N Engl J Med. 2016).\n\nReferencias:\n- Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism. 2019;92:121-35.\n- Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4: 579-91.\n- Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625-38.\n- Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, et al. Body fatness and cancer—viewpoint of the IARC Working Group. N Engl J Med. 2016;375:794-8.\n\n## 8 Señale la respuesta falsa en relación con el tratamiento médico de la obesidad:\n\nA. La combinación del agonista noradrenérgico fentermina con el antiepiléptico topiramato (15 mg/92 mg) ha demostrado su eficacia en la pérdida de peso y en el mantenimiento del peso perdido a 2 años.\nB. La lorcaserina es un agonista selectivo de los receptores 5-HT2C que inhibe el apetito a través de la vía melanocortinérgica (α-MSH-CART).\nC. La naltrexona estimula los receptores opioides de las neuronas productoras de β-endorfinas.\nD. El orlistat, sintetizado a partir de la lipostatina, inhibe la mayoría de las lipasas del tracto gastrointestinal, bloqueando la digestión de los triglicéridos de la dieta.\n\n## COMENTARIO\n\nLa naltrexona es un conocido antagonista opiáceo; por tanto, su acción es bloquear las endorfinas y no estimularlas. La naltrexona se emplea en el tratamiento de la obesidad en combinación con el bupropión, que se utiliza en la deshabituación tabáquica y como antidepresivo. El bupropión es un inhibidor de la recaptación de noradrenalina y dopamina que ejerce una acción anorexígena, actuando sobre las neuronas de la melanocortina (POMC) que, a su vez, libera α-MSH que actúa en los receptores de melanocortina-4 (MC4-R). Esta acción tiene un mecanismo de feedback, mediado por una β-endorfina, que anula esta acción anorexígena. Sin embargo, la asociación con naltrexona, al actuar como antagonista de los receptores µ-opioides, permite que la actividad del bupropión se mantenga durante largo tiempo.\n\nLas otras respuestas (A, B y D) son correctas.\n\nFigura 6. Mecanismo de acción de bupropión-naltrexona.\n\nα-MSH: hormona estimulante de melanocitos; POMC: proopiomelanocortina; R-MC\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}